Hold Aurobindo Pharma Ltd For Target Rs.1,775 by Prabhudas Liladhar Capital Ltd
Multiple growth drivers
Aurobindo Pharma’s (ARBP) Q2FY27 EBITDA stood at INR 21.6bn (up 28% YoY); ~7% above our estimates; aided by currency tailwinds, Lannett acquisition and higher EU revenues. US revenues improved both QoQ and YoY on the back of integration of Lannett portfolio during the quarter. The company has maintained its 21% OPM guidance for FY27E. In near term ramp up in PenG facility, Vizag pant commercialization will be key. We believe ARBP has multiple growth drivers in place with investments in vaccines, injectables, biosimilars and PLI which are expected to be reflected from FY27E/FY28E. Our FY27E and FY28E EPS stands increased by 4%. We retain our “Hold” rating with revised TP of INR 1,775/share; valuing at 18x Sept’28E EPS.
* Higher EU & US revenues YoY: Overall Revenue came in at INR 102.6bn, up 24% YoY, (we est INR 97bn). The YoY growth was aided by currency tailwind and low base. US revenues stood at USD 476mn, up 20% QoQ and 14% YoY (we est USD 460mn). Consolidation of Lannett portfolio supported during the quarter. EU sales up 25.2% YoY to INR 31bn, beat our estimate. ARV formulations improved 10% YoY to INR 3.6bn whereas RoW sales were up 16% YoY. API sales increased by 21% YoY.
* Steady OPM at 21%: Gross margins remain healthy at 61.2% (up 150 YoY and 80bps QoQ). Other expenses were up 24% YoY. Resultant EBITDA came in at INR 21.6bn up 28% YoY (we est INR 20.2bn). OPM stood at 21% up 70bps YoY. Tax rate higher at 33%. There was forex gain of INR 29mn. Adj for forex PAT at INR 11.2bn. Reported adj EPS of INR 19.2/share.
Please refer disclaimer at Report
SEBI Registration number is INH000000933
